Editing Ferrofluid (section)

====Medical applications====
Several ferrofluids were marketed for use as [[MRI contrast agent|contrast agents]] in [[magnetic resonance imaging]], which depend on the difference in magnetic relaxation times of different tissues to provide contrast.<ref name=app/><ref>{{cite journal|last1=Wang|first1=YX|title=Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application|journal=Quantitative Imaging in Medicine and Surgery|date=December 2011|volume=1|issue=1|pages=35–40|pmid=23256052|pmc=3496483|doi=10.3978/j.issn.2223-4292.2011.08.03}}</ref> Several agents were introduced and then withdrawn from the market, including Feridex I.V. (also known as Endorem and ferumoxides), discontinued in 2008;<ref>{{cite web |url=http://www.amagpharma.com/products/feridex_iv.php |title=Feridex - Products - AMAG Pharmaceuticals |publisher=Amagpharma.com |access-date=2012-06-20 |url-status=dead |archive-url=https://web.archive.org/web/20120615182847/http://www.amagpharma.com/products/feridex_iv.php |archive-date=2012-06-15 }}</ref> resovist (also known as Cliavist), 2001 to 2009;<ref>{{cite web|author=Softways |url=http://www.mr-tip.com/serv1.php?type=db1&dbs=Resovist |title=Magnetic Resonance TIP - MRI Database : Resovist |publisher=Mr-tip.com |access-date=2012-06-20}}</ref> Sinerem (also known as Combidex), withdrawn in 2007;<ref>{{cite web |url=http://www.thefreelibrary.com/AMAG+Pharmaceuticals,+Inc.+Announces+Update+on+Sinerem(TM)+in+Europe.-a0172378541 |title=AMAG Pharmaceuticals, Inc. Announces Update on Sinerem(TM) in Europe. - Free Online Library |publisher=Thefreelibrary.com |date=2007-12-13 |access-date=2012-06-20 |archive-date=2019-03-23 |archive-url=https://web.archive.org/web/20190323160818/https://www.thefreelibrary.com/AMAG+Pharmaceuticals%2c+Inc.+Announces+Update+on+Sinerem(TM)+in+Europe.-a0172378541 |url-status=dead }}</ref> Lumirem (also known as Gastromark), 1996<ref>{{cite web |url=http://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=105 |title=Newly Approved Drug Therapies (105) GastroMARK, Advanced Magnetics |publisher=CenterWatch |access-date=2012-06-20 |archive-date=2011-12-29 |archive-url=https://web.archive.org/web/20111229114636/http://centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=105 |url-status=dead }}</ref> to 2012;<ref>{{cite web|title=AMAG Form 10-K For the Fiscal Year Ended December 31, 2013|url=https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/a2218084z10-k.htm|publisher=SEC Edgar}}</ref><ref>{{cite web|title=NDA 020410 for GastroMark|url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020410|archive-url=https://web.archive.org/web/20170212171148/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020410|url-status=dead|archive-date=February 12, 2017|publisher=FDA|access-date=12 February 2017}}</ref> Clariscan (also known as PEG-fero, Feruglose, and NC100150), development of which was discontinued due to safety concerns.<ref>{{cite journal |doi=10.3978/j.issn.2223-4292.2011.08.03 |first1=Yi-Xiang J. |last1=Wang |year=2011 |title=Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application |journal=Quantitative Imaging in Medicine and Surgery |pmid=23256052 |volume=1 |issue=1 |pages=35–40 |pmc=3496483 }}</ref>